Immunomedics, Inc. (NASDAQ:IMMU) Director Brian A. Markison sold 8,390 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $11.89, for a total transaction of $99,757.10. Following the sale, the director now owns 99,178 shares of the company’s stock, valued at $1,179,226.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Immunomedics, Inc. (NASDAQ:IMMU) traded down $0.37 during mid-day trading on Thursday, reaching $11.02. 1,548,100 shares of the company’s stock were exchanged, compared to its average volume of 3,086,685. The company has a debt-to-equity ratio of -0.29, a current ratio of 0.74 and a quick ratio of 0.74. Immunomedics, Inc. has a one year low of $3.01 and a one year high of $14.48.

WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/11/23/brian-a-markison-sells-8390-shares-of-immunomedics-inc-immu-stock.html.

A number of equities research analysts have issued reports on IMMU shares. Jefferies Group LLC upped their price target on shares of Immunomedics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Monday, October 9th. Zacks Investment Research upgraded shares of Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a report on Wednesday, October 4th. Finally, BidaskClub upgraded shares of Immunomedics from a “hold” rating to a “buy” rating in a report on Wednesday, August 23rd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $15.33.

A number of hedge funds have recently added to or reduced their stakes in IMMU. FMR LLC boosted its holdings in Immunomedics by 260.6% during the second quarter. FMR LLC now owns 5,496,851 shares of the biopharmaceutical company’s stock valued at $48,537,000 after acquiring an additional 3,972,388 shares during the period. Palo Alto Investors LLC bought a new stake in Immunomedics during the second quarter valued at about $26,582,000. NEA Management Company LLC bought a new stake in Immunomedics during the third quarter valued at about $38,762,000. State Street Corp raised its position in shares of Immunomedics by 118.2% during the first quarter. State Street Corp now owns 3,513,549 shares of the biopharmaceutical company’s stock valued at $22,730,000 after buying an additional 1,903,355 shares during the last quarter. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Immunomedics during the second quarter valued at about $10,570,000. Institutional investors own 62.61% of the company’s stock.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.